ZYME Zymeworks (ZYME) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001937653
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
85
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $0 priced
What the filings say about ZYME
Insiders, 180 days
-$357.6K net sold
1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$349.4K
1 notice
Zymeworks insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Zymeworks Inc. insiders sold a net $357.6K of stock across 79 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 59.6% of the 23,205 shares held after it.
- No other insider sold within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Head of R&D Schayowitz Adam sold about $357.6K of ZYME on Oct 9, 2026; 85 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 4.6% of the 132,913 shares held after it.
- 3 other insiders sold within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chief Operating Officer Hollywood Mark sold about $138.7K of ZYME on Jan 12, 2026; 3 other insiders sold within 30 days and 85 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jan 5, 2026.
- The trade is 34.9% of the 26,708 shares held after it.
- 3 other insiders sold within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chief Medical Officer Smith Jeffrey T L sold about $211.1K of ZYME on Jan 12, 2026; 3 other insiders sold within 30 days and 85 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jan 5, 2026.
- The trade is 19.7% of the 48,497 shares held after it.
- 3 other insiders sold within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Moore Paul Andrew sold about $216.7K of ZYME on Jan 12, 2026; 3 other insiders sold within 30 days and 85 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jan 5, 2026.
- The trade is 13.4% of the 226,842 shares held after it.
- 3 other insiders sold within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chair & CEO Galbraith Kenneth sold about $689.7K of ZYME on Jan 12, 2026; 3 other insiders sold within 30 days and 85 funds added in the latest 13F quarter.79 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$357.6K over 180 days
-$357.6K over 90 days
below 53% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
85 funds bought in last quarter
more than 62% of Pharma & Biotech
Revenue
+38.9% year over year
more than 73% of Pharma & Biotech
Margin
-76.6% net margin
below 54% of Pharma & Biotech
Buybacks
$128.1M repurchased, FY to 2026-06-30
more than 70% of Pharma & Biotech
Short interest
8.4% of the float short (float per yahoo 2026-10-27) · 4.4 days to cover · settled 2026-10-15
more than 64% of Pharma & Biotech
What changed in the last 30 days
Oct 9EVP, Head of R&D Schayowitz Adam sold $357.6K (Oct 9)
Oct 9officer Adam Schayowitz filed to sell $349.4K by Oct 9 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch ZYME
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+65.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ZYME: institutional holders (13F)
13F holdings, latest reported quarter
22,970,388 sh
$600.4M
7,000,000 sh
$183.0M
4,251,030 sh
$111.1M
4,182,953 sh
$109.3M
3,649,142 sh
$95.4M
Congress trades in ZYME
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ZYME planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Adam Schayowitz
Filed 2026-10-09
$349.4K
ZYME mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Tema Oncology ETF
$2.7M position · as of 2026-05-31
1.5%
DANA EPIPHANY SMALL CAP EQUITY FUND
$523.0K position · as of 2026-07-31
1.5%
Nomura Small Cap Growth Fund
$15.7M position · as of 2026-06-30
1.3%
SFT Nomura Small Cap Growth Fund
$2.6M position · as of 2026-06-30
1.3%
Nomura VIP Small Cap Growth Series
$3.1M position · as of 2026-06-30
1.3%
Virtus Biotech Etf
$1.3M position · as of 2026-07-31
1.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Kenneth Galbraith
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$3.4M
$4.4M
$1.7M
-37%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $357.6K sold by insiders over 180 days, 85 funds added last quarter, $349.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ZYME financials
Revenue growth
+38.9%
XBRL, annual
Net margin
-76.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$37.1M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ZYME
| FY Dec 2025 | $106.0M |
| FY Dec 2024 | $76.3M |
| FY Dec 2023 | $76.0M |
| FY Dec 2022 | $412.5M |
| FY Dec 2021 | n/a |
| Jun 2026 | $4.6M |
| Mar 2026 | $2.4M |
| Dec 2025 | $2.5M |
| Sep 2025 | $27.6M |
| Jun 2025 | $48.7M |
| Mar 2025 | $27.1M |
| Dec 2024 | $31.0M |
| Sep 2024 | $16.0M |
At each fiscal year end
Single quarter
Net margin, TTM
-404.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ZYME
| FY Dec 2025 | -76.6% |
| FY Dec 2024 | -160.8% |
| FY Dec 2023 | -156.1% |
| FY Dec 2022 | +30.1% |
| FY Dec 2021 | n/a |
| Jun 2026 | -980.8% |
| Mar 2026 | -1,834% |
| Dec 2025 | -1,639% |
| Sep 2025 | -71.0% |
| Jun 2025 | +4.8% |
| Mar 2025 | -83.5% |
| Dec 2024 | -75.8% |
| Sep 2024 | -186.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$120.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ZYME
| FY Dec 2025 | -$34.5M |
| FY Dec 2024 | -$112.0M |
| FY Dec 2023 | -$120.8M |
| FY Dec 2022 | $136.0M |
| FY Dec 2021 | n/a |
| Jun 2026 | -$31.9M |
| Mar 2026 | -$45.9M |
| Dec 2025 | -$10.8M |
| Sep 2025 | -$31.8M |
| Jun 2025 | $11.6M |
| Mar 2025 | -$3.4M |
| Dec 2024 | -$41.8M |
| Sep 2024 | -$6.8M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity ZYME
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt ZYME
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-72.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ZYME
| FY Dec 2025 | -26.7% |
| FY Dec 2024 | -30.5% |
| FY Dec 2023 | -24.8% |
| FY Dec 2022 | +33.5% |
| FY Dec 2021 | -64.3% |
| Jun 2026 | -72.3% |
| Mar 2026 | -42.0% |
| Dec 2025 | -26.7% |
| Sep 2025 | -18.5% |
| Jun 2025 | -19.9% |
| Mar 2025 | -29.8% |
| Dec 2024 | -30.5% |
| Sep 2024 | -28.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-37.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ZYME
| FY Dec 2025 | -20.0% |
| FY Dec 2024 | -23.5% |
| FY Dec 2023 | -19.3% |
| FY Dec 2022 | +24.0% |
| FY Dec 2021 | -54.4% |
| Jun 2026 | -37.2% |
| Mar 2026 | -22.7% |
| Dec 2025 | -20.0% |
| Sep 2025 | -14.3% |
| Jun 2025 | -15.9% |
| Mar 2025 | -23.2% |
| Dec 2024 | -23.5% |
| Sep 2024 | -21.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ZYME
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-43.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ZYME
| FY Dec 2025 | -27.3% |
| FY Dec 2024 | -30.5% |
| FY Dec 2023 | -25.6% |
| FY Dec 2022 | +30.0% |
| FY Dec 2021 | n/a |
| Jun 2026 | -43.2% |
| Mar 2026 | -28.4% |
| Dec 2025 | -27.3% |
| Sep 2025 | -18.6% |
| Jun 2025 | -19.9% |
| Mar 2025 | -29.1% |
| Dec 2024 | -30.5% |
| Sep 2024 | -31.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ZYME
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 4.18x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value ZYME
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-5.9%
TTM free cash flow over market value at close 2026-10-27
FCF yield ZYME
| FY Dec 2025 | -1.8% |
| FY Dec 2024 | -11.1% |
| FY Dec 2023 | -16.6% |
| FY Dec 2022 | +27.5% |
| FY Dec 2021 | n/a |
| Jun 2026 | -6.3% |
| Mar 2026 | -4.2% |
| Dec 2025 | -1.8% |
| Sep 2025 | -5.1% |
| Jun 2025 | -4.6% |
| Mar 2025 | -9.4% |
| Dec 2024 | -11.1% |
| Sep 2024 | -6.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ZYME
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $106.0M | $76.3M | $76.0M | $412.5M |
| Operating income | -$92.5M | -$137.1M | -$138.1M | $130.5M |
| Net income | -$81.1M | -$122.7M | -$118.7M | $124.3M |
| EPS (diluted) | -1.08 | -1.62 | -1.72 | 1.90 |
| Operating cash flow | -$33.0M | -$110.1M | -$118.3M | $144.1M |
| Cash | $41.2M | $66.1M | $157.6M | $400.9M |
| Buybacks | $41.7M | $30.1M | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
ZYME Stock Sonar score 5/7 axes
Find similar shapesCompareZYME ranks highest on growth (73rd percentile) and institutional and government (62nd), and lowest on insider conviction (22nd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ZYME filings, in plain words
Are Zymeworks insiders buying or selling ZYME?
In the 180 days to 2026-10-28, Zymeworks insiders were net sellers, a net $357.6K across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of ZYME?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $349.4K of stock; the latest, by Adam Schayowitz, was filed 2026-10-09.
Read the full summary
In the 180 days to 2026-10-28, Zymeworks insiders were net sellers of ZYME, a net $357.6K across purchases and sales reported on Form 4 by 1 seller. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $349.4K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
